Accumulated quality-adjusted life years gained, cost, and cost-effectiveness of selected scenarios.

<p>Accumulated quality-adjusted life years gained, cost, and cost-effectiveness of selected scenarios.</p

Parameter values for cost-effectiveness analysis.

<p>Parameter values for cost-effectiveness analysis.</p

Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men - Fig 1

<p><b>a-b: Incremental cost-effectiveness of PrEP (cost per QALY gained in thousands of US$)</b> *Combines drug cost, physician visits, and laboratory testing: drug cost:$10711/year, cost of physician visits: $1035/year, cost of renal function test:$30/year, cost of HIV testing: $108/year ^†Drug cost:$10711/year ^‡Drug cost: $6427/year ^§Drug cost:$4284/year ^‖Drug cost: 2142/year ^#Dominated refers to cost-effectiveness scenarios with higher cost and worse outcomes. c-d: PrEP drug cost stratified by cost per QALY threshold. *Current drug cost estimated at 10711.</p

One-way sensitivity analysis of PrEP cost-effectiveness (in US$).

<p>The black vertical line represents the base case-scenario relative to no PrEP ($64,000 per QALY gained). Blue bars represent the low value of the range, and red bars represent the high value of the range. Bars to the left of the base case scenario represent more favorable scenarios. Only parameters which affected the cost-effectiveness ratio by more than 50% in either direction are shown.</p

Individual HIV Risk versus Population Impact of Risk Compensation after HIV Preexposure Prophylaxis Initiation among Men Who Have Sex with Men - Fig 2

<p>The expected rate of HIV acquisition per 1000 discordant exposures for all MSM (Panel A), and for MSM who were currently using PrEP (Panel B) or not using PrEP at the time of exposure (Panel C), by the interaction of relative levels of condom-related risk compensation (RC) and PrEP medication adherence profile in which compensation occurred. Panel D shows the amount of person-time on PrEP per 100 possible person-weeks for susceptible MSM. The red line depicts RC in all four PrEP adherence profiles (high, medium, low, and non-adherent), the blue in the top three (high, medium, low) green in the top two (high and medium) and purple in the high only. The horizontal dashed lines shows a comparison of the two outcomes (incidence and PIA) if RC were not to occur (0% RC). All points summarize the empirical distribution of 250 simulations of each scenario.</p

Relative and standardized prevalence of major depression by gender and four demographic characteristics — Medical Monitoring Project (MMP), 2009 and Behavioral Risk Factor Surveillance System (BRFSS), 2006 and 2008.

<p>wgt. %  =  weighted %; SE  =  standard error; PR  =  prevalence ratio (unadjusted); SPR  =  standardized prevalence ratio; 95% CI = 95% confidence intervals.</p><p>Responses to the Eight-item Patient Health Questionnaire were used to define “major depression” according to criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4^th Edition.</p

HIV exposure model equation: The estimated the probability of having ≥1 UAI partner with HIV transmission risk (i.e. HIV viral load >400 copies/ml).

<p>In this equation, <i>k</i> = number of UAI partners with transmission risk (<i>k</i>≤<i>m</i>); <i>m</i> = number of male UAI partners (m = 0 to ∞); <i>r</i> = black or white non-Hispanic race/ethnicity (r = 1, 2); <i>i</i> = race/ethnicity, same as <i>r</i>, and including a third level for ‘other’ non-black or non-white race/ethnicity (<i>i</i> = 1,2,3); <i>T_r,T_i</i> = race-specific %VL400 among male UAI partners; <i>E_r</i> = proportion of participants reporting exclusively same-race UAI partners, among race <i>r</i>; <i>A_{r, i}</i> = the proportion of UAI partners who were race/ethnicity <i>i</i>, among participants of race <i>r</i> reporting inter-racial UAI partners.</p

Individual-Level Risk and Time on PrEP by Risk Compensation Level, by PrEP Adherence Level and Partnership Types, among US MSM.

<p>Individual-Level Risk and Time on PrEP by Risk Compensation Level, by PrEP Adherence Level and Partnership Types, among US MSM.</p

The continuum of HIV care for black and white MSM in the <i>InvolveMENt</i> study.

<p>Complete data on linkage to and retention in HIV care are not available for this study.</p

Weighted percentage of HIV-infected adults receiving medical care in the United States who met criteria for current depression^*, by type of depression and selected self-reported characteristics — Medical Monitoring Project, 2009.

<p><i>*</i>Based on 4,168 persons who completed the <i>Eight-item Patient Health Questionnaire</i> (PHQ-8) depression scale<i>;</i>^†Male-to-female or female-to-male.</p><p>wgt. row%  =  weighted row %; 95% CI = 95% confidence intervals.</p><p>Responses to the PHQ-8 were used to define “Major depression” and “Other depression” according to criteria from the <i>Diagnostic and Statistical Manual of Mental Disorders, 4^th Edition</i>. Any depression is the presence of either major depression or other depression.</p